Pharma Tax Loophole: Pfizer, Merck, J&J Under Fire
- Two Democratic lawmakers are scrutinizing the tax bills of major pharmaceutical companies,questioning whether they support extending tax cuts in the Republican reconciliation bill.
- In letters to each company, Warren and Schakowsky contend that these firms avoided U.S.
- The lawmakers argue that this exemplifies how the tax code benefits wealthy pharmaceutical corporations,enabling them to profit from Americans through high drug prices while evading their fair share...
Senators Warren and Schakowsky are demanding answers, challenging the tax practices of Big Pharma giants Pfizer, Merck and Johnson & Johnson. Our investigation reveals how these companies may have exploited tax loopholes, perhaps minimizing their federal tax contributions.The primarykeyword, pharmaceutical industry, is under intense scrutiny for its role in allegedly shifting profits offshore, facilitated, arguably, by the 2017 Tax Cuts and Jobs Act. This secondarykeyword, tax loophole, has allowed these corporations to potentially evade what might potentially be their fair share of taxes while lobbying for extended tax breaks. The article delves into the financial maneuvers, exploring how these practices might benefit wealthy companies at the consumer’s expense. news Directory 3 breaks down potential reforms, and the potential for a $100 billion revenue increase. Discover what’s next in this evolving story.
Lawmakers Question Big Pharma’s Tax Practices Amid GOP Bill Debate
Updated June 18,2025
Two Democratic lawmakers are scrutinizing the tax bills of major pharmaceutical companies,questioning whether they support extending tax cuts in the Republican reconciliation bill. Sen. Elizabeth Warren, D-Mass., and Rep. Jan Schakowsky, D-Ill., have targeted Pfizer, Merck, Johnson & Johnson, AbbVie, and Amgen, alleging they paid minimal federal taxes on billions in profits.
In letters to each company, Warren and Schakowsky contend that these firms avoided U.S. taxes by shifting profits to offshore subsidiaries in countries with lower tax rates, such as Ireland and Bermuda. They assert this practice was facilitated by a provision in President Donald Trump’s 2017 Tax Cuts and Jobs Act, wich they say incentivized multinational companies to move profits and operations overseas.
The lawmakers argue that this exemplifies how the tax code benefits wealthy pharmaceutical corporations,enabling them to profit from Americans through high drug prices while evading their fair share of taxes.They also inquired whether the companies’ lobbying efforts aimed to maintain this tax loophole in Trump’s “One Big Gorgeous bill Act,” passed by the house in May.
Johnson & Johnson, as an example, reportedly spent over $150,000 lobbying on international tax issues in the fourth quarter of 2024 alone, according to data compiled by OpenSecrets.
Warren saeid it woudl be a “slap in the face” to expand tax loopholes for pharmaceutical companies making billions while overcharging americans. She added that these companies need to be held accountable for prioritizing profits over people.
The lawmakers requested each drugmaker to respond by July 1, including details on their role in lobbying for extensions of the tax breaks and their estimated federal tax liabilities. A J&J spokesperson said the company looks forward to clarifying its “meaningful U.S. tax contributions and cooperatively responding to Senator Warren and Representative Schakowsky’s letter.”
The letters cited a March analysis by the Council on Foreign relations, suggesting that reforming the offshore tax loophole could generate at least $100 billion over 10 years.
This isn’t the first time pharmaceutical companies’ tax practices have faced scrutiny. A previous report accused Pfizer of employing a “round-tripping” tactic to avoid U.S. income tax on $20 billion in domestic drug sales in 2019.
What’s next
The multitrillion-dollar tax and spending package is now in the senate, where its provisions face potential revisions. any Democratic effort to eliminate the offshore tax loophole faces an uphill battle given the Republican majority.